Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Accumulated Depreciation & Amortization (2021 - 2026)

Indivior Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $2.0 million for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 33.33% year-over-year to $2.0 million; the TTM value through Mar 2026 reached $2.0 million, down 33.33%, while the annual FY2025 figure was $10.0 million, 37.5% down from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $2.0 million at Indivior Pharmaceuticals, down from $10.0 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $16.0 million in Q4 2022 and troughed at $2.0 million in Q1 2026.
  • A 5-year average of $8.1 million and a median of $7.0 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 166.67% in 2022 and later tumbled 57.14% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $16.0 million in 2022, then dropped by 6.25% to $15.0 million in 2023, then increased by 6.67% to $16.0 million in 2024, then tumbled by 37.5% to $10.0 million in 2025, then plummeted by 80.0% to $2.0 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for INDV at $2.0 million in Q1 2026, $10.0 million in Q4 2025, and $8.0 million in Q3 2025.